Median-based incremental cost-effectiveness ratios with censored data

Heejung Bang, Hongwei Zhao

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Cost-effectiveness is an essential part of treatment evaluation, in addition to effectiveness. In the cost-effectiveness analysis, a measure called the incremental cost-effectiveness ratio (ICER) is widely utilized, and the mean cost and the mean (quality-adjusted) life years have served as norms to summarize cost and effectiveness for a study population. Recently, the median-based ICER was proposed for complementary or sensitivity analysis purposes. In this article, we extend this method when some data are censored.

Original languageEnglish (US)
JournalJournal of Biopharmaceutical Statistics
StateAccepted/In press - Nov 11 2015


  • Censoring
  • cost-effectiveness analysis
  • ICER
  • median

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Statistics and Probability


Dive into the research topics of 'Median-based incremental cost-effectiveness ratios with censored data'. Together they form a unique fingerprint.

Cite this